申请人:LEO Pharma A/S
公开号:US20180258080A1
公开(公告)日:2018-09-13
The present invention relates to a compound according to formula (I)
wherein R
1
is selected from the group consisting of 5- and 6-membered heteroaryl, (C
1
-C
6
)alkyl, (C
3
-C
6
)cycloalkyl, (4-6)-membered heterocycloalkyl and phenyl; R
2
is selected from (C
1
-C
3
)alkyl and halo(C
1
-C
3
)alkyl; R
3
is selected from phenyl, 5-membered heteroaryl and 6-membered heteroaryl; R
4
is selected from hydrogen, halogen, (C
1
-C
4
)alkyl and halo(C
1
-C
4
)alkyl; X
1
is selected from CH, C(R
b
) and N, X
2
is selected from CH and N; Y is selected from —NH— and —O—; m is 0 or 1; n is 0 or 1; L represents a bond, —O—, —NH— or —N(R
c
)—; or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.